Table of Contents
ISRN Immunology
Volume 2011, Article ID 536484, 3 pages
http://dx.doi.org/10.5402/2011/536484
Research Article

Advantages of Sirolimus in a Calcineurin-Inhibitor Minimization Protocol for the Immunosuppressive Management of Kidney Allograft Recipients

1Department of Microbiology and Immunology, Faculty of Medicine, American University of Beirut, 1107 2020 Beirut, Lebanon
2Department of Surgery, Faculty of Medicine, American University of Beirut, 1107 2020 Beirut, Lebanon
3Department of Internal Medicine, Faculty of Medicine, American University of Beirut, 1107 2020 Beirut, Lebanon

Received 5 May 2011; Accepted 25 June 2011

Academic Editors: T. Koshiba, M. Muro, and E. H. Weiss

Copyright © 2011 Elias A. Rahal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Levey, J. Coresh, K. Bolton et al., “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, no. 2, pp. S1–S266, 2002. View at Google Scholar · View at Scopus
  2. P. F. Halloran, “Immunosuppressive drugs for kidney transplantation,” The New England Journal of Medicine, vol. 351, no. 26, pp. 2715–2729, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. F. Citterio, “Steroid side effects and their impact on transplantation outcome,” Transplantation, vol. 72, no. 12, pp. SS75–SS80, 2001. View at Google Scholar · View at Scopus
  4. M. Naesens, D. R. J. Kuypers, and M. Sarwal, “Calcineurin inhibitor nephrotoxicity,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 481–508, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. P. Dupont and A. N. Warrens, “The evolving role of sirolimus in renal transplantation,” QJM, vol. 96, no. 6, pp. 401–409, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. A. N. Warrens, “The evolving role of mycophenolate mofetil in renal transplantation,” QJM, vol. 93, no. 1, pp. 15–20, 2000. View at Google Scholar · View at Scopus
  7. R. Marcn, “Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection,” Drugs, vol. 69, no. 16, pp. 2227–2243, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. J. Matas, D. Granger, D. B. Kaufman et al., “Steroid minimization for sirolimus-treated renal transplant recipients,” Clinical Transplantation, vol. 25, no. 3, pp. 457–467, 2011. View at Google Scholar
  9. S. M. Flechner, “Minimizing calcineurin inhibitor drugs in renal transplantation,” Transplantation Proceedings, vol. 35, no. 3, pp. 118S–121S, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. B. Khauli, A. Houjaij, S. Sawah et al., “Observations on quadruple immunosuppression maintenance therapy using rapamycin, low-dose cyclosporine, mycophenolate mofetil, and prednisone following ATG induction,” Transplantation Proceedings, vol. 37, no. 7, pp. 3031–3033, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. M. Abdelnoor, R. Ajib, M. Chakhtoura et al., “Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection,” Immunopharmacology and Immunotoxicology, vol. 31, no. 1, pp. 83–87, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. H. Chen, H. Luo, P. Daloze et al., “Long-term in vivo effects of Rapamycin on humoral and cellular immune responses in the rat,” Immunobiology, vol. 188, no. 3, pp. 303–315, 1993. View at Google Scholar · View at Scopus
  13. M. D. Pescovitz, B. K. Book, S. Henson et al., “The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin,” American Journal of Transplantation, vol. 3, no. 4, pp. 497–500, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Propper, J. Woo, A. M. Macleod, G. R. D. Catto, and A. W. Thomson, “The effects of rapamycin on humoral immunity in vivo: suppression of primary responses but not of ongoing alloantibody synthesis or memory responses,” Transplantation, vol. 54, no. 6, pp. 1058–1063, 1992. View at Google Scholar · View at Scopus
  15. P. I. Terasaki and M. Ozawa, “Predicting kidney graft failure by HLA antibodies: a prospective trial,” American Journal of Transplantation, vol. 4, no. 3, pp. 438–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. I. Terasaki and M. Ozawa, “Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial,” Transplantation, vol. 80, no. 9, pp. 1194–1197, 2005. View at Publisher · View at Google Scholar · View at Scopus